Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2853025 | 0.89 | ALDH1A1 (0.65) | ALDH1A1HPGDMAPTMAPK1GAA | |
| SCHEMBL14883365 | 0.84 | ALDH1A1 (0.57) | ALDH1A1HPGDMAPTMAPK1GAA | |
| SCHEMBL2852047 | 0.84 | ALDH1A1 (0.59) | ALDH1A1HPGDMAPTMAPK1GAA | |
| SCHEMBL2856061 | 0.83 | ALDH1A1 (0.58) | ALDH1A1MAPTMAPK1GAAMAPK14 | |
| SCHEMBL773204 | 0.83 | NR4A3 (0.78) | ALDH1A1MAPTMAPK1GAANR4A3 | |
| SCHEMBL17952720 | 0.82 | HPGD (0.67) | ALDH1A1HPGDMAPTMAPK1CYP3A4 | |
| SCHEMBL13593554 | 0.81 | ALDH1A1 (0.63) | ALDH1A1MAPTMAPK1GAANR4A3 | |
| SCHEMBL16615597 | 0.80 | ALDH1A1 (0.74) | ALDH1A1MAPTMAPK1LMNA | |
| SCHEMBL27808 | 0.80 | NR4A3 (0.61) | ALDH1A1MAPTMAPK1GAANR4A3 | |
| SCHEMBL14883363 | 0.80 | HPGD (0.65) | ALDH1A1HPGDMAPTMAPK1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | ICAGEN, INC. (US) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | SCN3A, TRPV3, HCN3 | ALDH1A1 3589/4885HPGD 1358/4885MAPT 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.